ArticleThoracic cancer2021

Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.

Zhansheng Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.